Temporary opening of the blood-brain barrier with the nitrone compound OKN-007

Towner, Rheal A. and Saunders, Debra and Lerner, Megan and Silasi Mansat, Robert and Yuan, Tian and Nyúl-Tóth, Ádám (2021) Temporary opening of the blood-brain barrier with the nitrone compound OKN-007. AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 11 (5). pp. 363-373. ISSN 2160-8407

Preview

Text TownerAmJ.pdf Download (1MB) | Preview

Abstract

The blood-brain barrier (BBB) is usually impermeable to several drugs, which hampers treatment of various brain-related diseases/disorders. There have been several approaches to open the BBB, including intracarotid infusion of hyperosmotic concentrations of arabinose, mannitol, oleic or linoleic acids, or alkylglycerols, intravenous infusion of bradykinin B2, administration of a fragment of the ZO toxin from vibrio cholera, targeting specific components of the tight junctions (e.g. claudin-5) with siRNA or novel peptidomimetic drugs, or the use of ultrasound with microbubbles. We propose the use of a low molecular weight (MW), nitrone-type compound, OKN-007, which can temporarily open up the BBB for 1-2 hours. Gadolinium (Gd)-based compounds assessed ranged in MW from 546 (Gd-DTPA) to 465 kDa (beta-galactosidase Gd DOTA). We also included an albumin-based CA (albumin-Gd-DTPA-biotin) for assessment, as well as an antibody (Ab) against a neuron-specific biomarker conjugated to Gd-DOTA (anti-EphB2-Gd-DOTA). For the anti-EphB2 (goat Ab)-Gd-DOTA assessment, we utilized an anti goat Ab conjugated with horse radish peroxidase (HRP) for confirmation of the presence of the anti-EphB2-Gd-DOTA probe. In addition, a Cy5 labeled anti-EphB2 Ab was co-administered with the anti-EphB2-Gd-DOTA probe, and assessed ex vivo. This study demonstrates that OKN-007 may be able to temporarily open up the BBB to augment the delivery of various compounds ranging in MW from as small as similar to 550 to as large as similar to 470 kDa. This compound is an investigational new drugfor glioblastoma (GBM) therapy in clinical trials. The translational capability for human use to augment the delivery of non-BBB-permeable drugs is extremely high.

Actions (login required)

Edit Item